Vanderbilt TB Center News

VTC Hosts TB/HIV R01 Meeting

Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our TB/HIV grant "Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis" (NIH R01AI120790-04). The event, which took place on April 26th and 27th, included presentations on the results and findings of each working group, breakout sessions, and discussions on future steps to be taken and larger goals of the research.

VUMC lands Grant to build top-line Biosafety Facility

Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. When the renovation of about 3,500 square feet of existing space is completed, the facility will include three BSL3 suites with separate entrances and seven procedure rooms capable of securely containing multiple organisms at the second-highest biosafety level.

VUMC investigators attend RePORT-International Annual Meeting

VUMC investigators and staff, Timothy Sterling, Yuri van der Heijden, Stephany Duda, Marina Figueiredo, Fernanda Mauri, Megan Turner, and Austin Katona; attended the annual RePORT International meeting that was held in Cape Town, South Africa, September 7 and 8, 2022. The meeting included all seven regions of RePORT: Brazil, China, South Africa, South Korea, India, Indonesia, and the Philippines. It was a successful meeting full of presentations and collaborative discussions.

WHO Global TB Report was released!

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

Publication Announcement: “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis"

The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.

Vanderbilt TB Center FY 2020 Annual Report has been released!

The TB Center Annual Report from FY 2020 has now been published, detailing Center activities, research, and funding for the 2020 fiscal year. See the link below to download the full report. We look forward to continued progress toward our research goals in the current year.

Heather Ewing presents MPH Thesis on TB and Stigma

Heather Ewing, MA(c), MPH(c), presented her MPH thesis on Friday, March 2, titled "Knowledge of Tuberculosis is Associated with Greater Expression of Stigma in Brazil". This project stemmed from a Vanderbilt Trans-Institutional Program grant (TIPs), which focused on healthcare in Brazil.